Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Mole101on Jun 05, 2021 1:32pm
178 Views
Post# 33336176

Race between vaccines and variants is back on as B.1.617 ...

Race between vaccines and variants is back on as B.1.617 ...

Great article open it up at bottom of page, I just highlighted the part I found more interesting to me..,


Canada lacks 'clear view' of B.1.617

One advantage we had with B.1.1.7 that we don't with B.1.617 was that it was easy to screen for it due to a lucky break — a simple genetic marker that appeared on test samples called an S Gene failure that signalled the variant was likely present. 

But with B.1.617 we're not so lucky, and experts say we could be flying blind as cases may be rapidly growing behind the scenes in Canada due to a lack of surveillance. 

"We don't have the ability to see it as well as when we're screening for B.1.1.7, because we don't have that quick screening test," said Prof. Ashleigh Tuite, an infectious diseases epidemiologist and assistant professor at the University of Toronto's Dalla Lana School of Public Health.

Tuite says researchers have been forced to try to calculate the spread of B.1.617 with "incomplete data," but there are early signs that an "unknown" variant is spreading in the background in Canada.

"All signs point to that being B.1.617, but we don't have a perfectly clear view on what's happening," she said. "The challenge right now is just understanding the extent of the issue and how geographically widespread it is right now." 

A recent cluster of COVID-19 in Newfoundland & Labrador that has grown to at least 60 cases was confirmed as being caused by B.1.617, while outbreaks of the variant have also been detected in B.C., Quebec, Alberta and Ontario.

Troy Day, a member of the Ontario Modelling Consensus Table and a mathematician at Queen's University in Kingston, Ont., says B.1.617 will likely overtake B.1.1.7 to become the new dominant strain in Ontario by next month. 

 

https://www.google.ca/amp/s/www.cbc.ca/amp/1.6053976

<< Previous
Bullboard Posts
Next >>